- Comment: This article "sings praises" -- inappropriate for an encyclopedia article. The photos with famous people do not belong here. Also, the early life section is entirely unreferenced. No unreferenced material is allowed in biographical articles. Plus, it really doesn't matter what sports he did as a child. LaMona (talk) 22:42, 7 March 2016 (UTC)
Richard B. Hollis | |
---|---|
Born | San Mateo, CA, U.S. | December 8, 1952
Education | San Francisco State University (B.A.) |
Occupation(s) | Entrepreneur and businessman |
Years active | 1974–present |
Employer(s) | Holonis, Inc. |
Title | CEO of Holonis |
Website | www |
Richard B. Hollis is an American business leader, who founded of Holonis, Inc., a San Diego based software company. He is the company's current Chairman and CEO. Hollis began his career in product sales with Baxter Travenol (today Baxter International), one of the world’s largest healthcare suppliers. Subsequent to Baxter, he was hired by IMED Corporation in San Diego as their west coast sales manager, where he helped launch the world’s first volumetric intravenous infusion device.[1]
From 1986 to 1990 Hollis was an early member of the biotechnology company Genentech Inc., where he led the product launches for Protropin (Human Growth Hormone) and TPA (Tissue Plasminogen Activator), a drug for dissolving clots in heart attack victims.[2] He also founded Hollis-Eden Pharmaceuticals[3], a San Diego based biotechnology company in 1993.[4]
Biography
Richard Hollis is the fifth of nine children, born to Edward Hollis, a multilingual American military interpreter (and prisoner of war), in the Pacific during World War II, and Grace Borras Hollis. His parents settled and raised their family in San Mateo, CA. Beginning at the age of six, his active participation and achievements at the local Boys' Club culminated in the 1966 Boy of the Year Award[5][6] at the age of 13. Hollis graduated from San Francisco State University in 1977 with a degree in Psychology.[7]
Career
Hollis' first job opportunity after college was with Baxter Travenol[8][9], where he helped launched the world's first parenteral and enteral feeding solutions to hospitals and nursing homes.
The success of these products attracted the attention of San Diego based IMED Corporation, which was launching the world’s first volumetric intravenous pump.[10] At IMED he was rapidly promoted, culminating in the Divisional Manager of the Year in 1984.[1] Market leading product adoption and sales of the volumetric intravenous pump resulted in IMED’s rapid growth and the notice of pharmaceutical giant Warner Lambert. IMED was subsequently acquired by Warner Lambert, and was the largest healthcare acquisition of a privately held company at the time.[11]
HiTech - Biotech
Since he already had experience in the healthcare industry, Hollis was offered and accepted a position[12] with Genentech, the bay area's first biotechnology company to successfully go public and get a product approved by the FDA. In this role he led the newly formed Western Business Unit in preparation for launching Genentech’s first commercial products.[1]
Hollis formed initial marketing and sales strategies as well as recruiting sales teams and sales managers. In 1986-87 Genentech introduced two new radical drugs into the market, laying the foundation for the biotech revolution of the 1980's.[13] The product launches resulted in Hollis receiving Genentech’s Manager of the Year award in 1988.
Next Hollis joined Instromedix[14], a medical device company that had the world’s first trans-telephonic cardiac event monitor, named “the King of Hearts."[15][16] Later he was recruited by Bioject Medical as Executive Vice President of Marketing and Sales, later promoted to Chief Operating Officer[17], where he positioned the company’s initial public offering. He proceeded to re-imagine the product[18] winning awards from Business Week's Annual Design Award[19], and the Red Dot Academy for outstanding design of a medical device, which in turn led to partnerships[20] with both Eli Lilly and Kobayashi Pharmaceuticals.
Founder & Entrepreneur
In 1993, he founded Hollis-Eden Pharmaceuticals, Inc.[21], incorporated in 1994, and took public in 1997[22], serving as Founder, Chairman and Chief Executive Officer[23] for over 17 years.
The company's purpose was to serve humanity by developing products[24] to treat infectious diseases[25] and diseases related to aging[26][27] by exploring the metabolome of the adrenal glands, to discover new chemical structures as pharmaceutical drug candidates. This approach manifested the world’s first hormonal signaling technology platform[28] and produced multiple drug candidates[29][30] in several disease indications.[31]
He collaborated with both former President Bush[32] and the Speaker of the House, Senator Bill Frist, in support of passing the legislation of the Project BioShield[33][34], to protect American citizens from acts of terrorism resulting from the September 11, 2001 attack.[35][36] Hollis was invited to the Rose Garden at the White House by President Bush for the signing of Project BioShield for his work in Acute Radiation Syndrome[37], and has testified at several congressional hearings[38] on behalf of the pharmaceutical industry’s role[39] in emergency preparedness response to acts of terrorism from nuclear, biological, and chemical warfare. [40][41]
Shortly after 9/11, Hollis rang the opening bell at NASDAQ[42] at Times Square with former New York Mayor Rudy Giuliani[22] for his work in developing a medical countermeasure to protect citizens from a radiation fallout due to a nuclear blast.[43]
Hollis was featured on a 60 Minutes special, “The Worst-Case Scenario” [44] that addressed whether the government was taking proper precaution to safeguard the American people from a terrorist nuclear attack[45][46].
Hollis also worked with the leaders in Africa in the fight against infectious diseases.[47] Subsequently, Hollis was invited to South Africa to meet with Nelson Mandela at his home to discuss HIV/AIDS, Tuberculosis, and Malaria research, where he also toured hospitals, clinics, and research facilities to set up human clinical trials. Hollis also met with past president Thabo Mbeki, current president Jacob Zuma, as well as leading researchers from around the world, including the World Health Organization to further discuss the issues and solutions surrounding global infectious diseases.[48]
With all of Hollis’ experience in the industry spanning over decades, he was asked to be one of the authors of the book, Inside the Minds of Pharmaceutical Executives.[49]
Holonis & The Digital Age
Having spent the majority of his career within the biotech industry, Hollis began extensive research on the Internet and digital technology during the Great Recession in 2008-2009, which led him to discover that “code is code”, identifying programmable patterns between digital technology and biological systems.[50][51]
Hollis concluded that the fragmentation of the Internet, along with the acceleration of technology, was overwhelming business owners and hindering their ability to adapt to the new digital age of marketing. He had a vision to create a digital platform[52] that could evolve and grow like a living biological organism. With his son, Hayden Hollis, a business graduate from San Diego State University, they created a digital platform that integrated the fragmented parts of the Internet into a complete operating system[53] named the Holon Operating Platform Ecosystem (HOPE), predicated on the understanding and principles of Holons in the digital sphere.[54]
Holonis connects all the core modules and functions of the Internet into a collaborative platform system that creates independent digital spaces known as "HoloSpaces."[55]
Hollis then formed a team dedicated to the company’s vision.[56] Holonis made its beta debut[57] at the 2015 South By Southwest Interactive Festival (SXSWi) in Austin, Texas and was recognized in numerous news outlets[58] including STORES Magazine,[59] NewsWatch[60], and AdWeek.[61]
References
- ^ a b c "MEDICAL DEVICE EXECUTIVE JOINS BIOJECT - Free Online Library". www.thefreelibrary.com. December 19, 1991. Retrieved March 8, 2016.
- ^ Bylinsky, Gene (May 9, 1988). "Genentech Has a Golden Goose Egg". CNN Money. Retrieved February 26, 2016.
- ^ "Hollis-Eden Pharmaceuticals, Inc". The Wall Street Transcript. November 17, 2008.
- ^ Crabtree, Penni (June 20, 2004). "Selling Safety". The San Diego Union Tribune.
- ^ "The Times from San Mateo, California · Page 14". Newspapers.com. Retrieved March 7, 2016.
- ^ "The Times from San Mateo, California · Page 23". Newspapers.com. Retrieved March 7, 2016.
- ^ "Amendment No. 1 to Form 10-K". www.wikinvest.com. United States Securities and Exchange Commission. Retrieved March 7, 2016.
- ^ "Biotech firm gets funding for virus drug - Portland Business Journal". Portland Business Journal. Retrieved March 7, 2016.
- ^ "Baxter Travenol Net Up". The New York Times. April 27, 1988.
- ^ Kraul, Chris. "Imed's 1st Public Offering Could Raise $55 Million". The Los Angeles Times. Retrieved March 17, 2014.
- ^ "Warner-Lambert to Acquire IMED at Cost of $465 Million". The New York Times. June 8, 1982.
- ^ Richard B. Hollis – Hollis-eden Pharmaceuticals, Inc. (heph).
- ^ "FDA Approves Genentech's Drug to Treat Children's Growth Disorder". Genentech. October 18, 1985. Retrieved February 26, 2016.
- ^ "Instromedix Announces Launch of King of Hearts Express+ Auto-Trigger Cardiac Event Monitor; Latest Addition to Company's Market-Leading Transtelephonic Monitor Family."The Free Library. 13 Aug. 2001. Web. 1 Mar. 2016.
- ^ "Bioject Earns Business Week Sponsored Design Award". Retrieved February 28, 2014.
- ^ "Instromedix Announces Launch of King of Hearts Express+ Auto-Trigger Cardiac Event Monitor; Latest Addition to Company's Market-Leading Transtelephonic Monitor Family". The Free Library. August 13, 2001. Retrieved February 26, 2016.
- ^ “Bioject Appoints Chief Operating Officer.” The Free Library. 2016. Web. 26 Feb. 2016.
- ^ “Needleless injector.” JUSTIA Patents. 24 July 1992. Web. 26 Feb. 2016.
- ^ "A Shot In The Arm For Sales?". BloombergView. Retrieved March 9, 2016.
- ^ "Bioject Opens Southwest Region For Needle-Free Injector". The Free Library. February 24, 1993. Retrieved February 26, 2016.
- ^ "Daniel Burgess - Hollis-eden Pharmaceuticals Inc (heph)". The Wall Street Transcript. February 18, 2002. Retrieved March 3, 2016.
- ^ a b McEntee, Jennifer. "Hollis-Eden rings Nasdaq bell, toots its own horn". The San Diego Daily Transcript. Retrieved February 28, 2014.
- ^ Crabtree, Penni. "People to watch: Richard Hollis". Union-Tribune San Diego. Retrieved July 14, 2006.
- ^ “Creating the Future For 21st Century Global Medicine." AnnualReports.com. 2002. Web. 26 Feb. 2016.
- ^ Sellers, L.J. "It's All About Immunity". PharmExec.com.
- ^ "The Future of Biotech". BioWorld. Retrieved March 2, 2016.
- ^ "Hollis-Eden Pharmaceuticals Presents Positive Data Demonstrating HE3286 Provides Benefit in Animal Model of Ulcerative Colitis". www.drugs.com. October 8, 2007. Retrieved March 2, 2016.
- ^ Hollis-Eden Pharmaceuticals Presents Data Demonstrating Potential Therapeutic Benefits of Second-Generation Drug Candidates. BusinessWire. 12 September 2006
- ^ “Hollis Eden Pharmaceuticals Patents.” Google Patents. n.d. Web. 26 Feb. 2016.
- ^ "BP, refinery workers settle suit | The San Diego Union-Tribune". www.sandiegouniontribune.com. Retrieved March 2, 2016.
- ^ "Hollis-Eden Pharmaceuticals Presents Positive Data Demonstrating HE3286 Provides Benefit in Animal Model of Ulcerative Colitis". Drugs.com. Retrieved February 25, 2014.
- ^ Thompson, Mark (January 3, 2006). "Inside the Spore Wars". Time. Retrieved March 2, 2016.
- ^ "Project Bioshield would make local impact". www.sandiegouniontribune.com. The San Diego Union-Tribune. May 15, 2004. Retrieved March 2, 2016.
- ^ "Rates on short-term T-bills jump | The San Diego Union-Tribune". www.sandiegouniontribune.com. Retrieved March 2, 2016.
- ^ "Hormone May Prevent Dirty Bomb Deaths". WebMD. Retrieved March 3, 2016.
- ^ "A Radiation Antidote?". BloombergView. Retrieved March 3, 2016.
- ^ "Project BioShield to give small S.D. firms a market | The San Diego Union-Tribune". www.sandiegouniontribune.com. Retrieved March 7, 2016.
- ^ "Can BioShield Effectively Procure Medical Countermeasures That Safeguard the Nation? Testimony of Richard Hollis" (PDF). Committee on Homeland Security. April 18, 2007. Retrieved March 2, 2016.
- ^ "Hollis-Eden Pharmaceuticals Inc. (HEPH) CEO Scheduled To Testify On WMD Medical Countermeasures Before House Armed Services Committee". www.biospace.com. October 25, 2005. Retrieved March 2, 2016.
- ^ "Emerging Drug Developer: Hollis-Eden". FierceBiotech. Retrieved March 2, 2016.
- ^ Crabtree, Penni (June 20, 2004). "Selling safety". www.sandiegouniontribune.com. The San Diego Union-Tribune. Retrieved March 9, 2016.
- ^ "NASDAQ Memorable Market Opens". www.nasdaq.com. Retrieved March 8, 2016.
- ^ "Project BioShield: Linking Bioterrorism Threats and Countermeasure Procurement to Enhance Terrorism Preparedness". www.gpo.gov. July 12, 2005. Retrieved March 3, 2016.
- ^ Schorn, Daniel. “The Worst-Case Scenario.” 60 Minutes. 27 Jan. 2006. Web. 26 Feb. 2016.
- ^ Kaufman, Marc. “Company Criticizes HHS BioShield Effort.” Washington Post 28 Sept. 2005. Web. 26 Feb. 2016.
- ^ Caroll, John (October 1, 2007). "Traversing the Landscape Of Project BioShield". Biotechnology healthcare. 4 (5): 7–8. ISSN 1554-169X. PMC 2651710. PMID 22478669.
- ^ Pharmaceutical, Hollis-Eden, and PR Newswire. “Hollis-Eden Pharmaceuticals Receives Clearance from the South African Government to Initiate Additional HIV Clinical Trials.” PR Newswire, 27 Sept. 2000. Web. 26 Feb. 2016.
- ^ "Hollis-Eden Pharmaceuticals Releases Letter by South African Government Calling for Broad Support of its Phase III Drug Candidate in HIV, Infectious Disease". www.evaluategroup.com. December 5, 2002. Retrieved March 2, 2016.
- ^ Books, Aspatore. Inside the Minds: The Pharmaceutical Industry: Leading CEOs on Drug Development, Product Differentiation and the Future of Specialty Pharma. N.p.: Aspatore Books, 1 Aug. 2003. Web. 26 Feb. 2016.
- ^ "Holonis, The Digital Genome And The Next Generation Marketplace | PYMNTS.com". PYMNTS.com. Retrieved March 2, 2016.
- ^ Pilon, Annie. “Spotlight: Manage A Gazillion marketing platforms with Holonis.” SmallBizTrends. Small Business Trends, 20 May 2015. Web. 26 Feb. 2016.
- ^ "Holonis Brings All the Pieces Together for Your On-Line Marketing Needs". wsRadio.com. February 24, 2015. Retrieved March 2, 2016.
- ^ System and method for internet publishing, Hollis, Richard B., Hayden S. Hollis, Zachary Schenkler, and Arvind Morwal. System and Method for Internet Publishing. Investinghouse, Inc., assignee. Patent WO2013188815 A3. 1 May 2014..
- ^ "Entrepreneur Aims to Create New Commerce Ecosphere Based on Engagement Principles". blog.enterpriseengagement.com. Retrieved March 2, 2016.
- ^ “Holonis Launches Next-Generation Online Marketplace.” PRWeb, 24 Feb. 2015. Web. 26 Feb. 2016.
- ^ “Richard Hollis - Founder, Chairman and CEO of Holonis.” IdeaMensch, 26 May 2015. Web. 26 Feb. 2016.
- ^ Chamberlain, Lauryn Chamberlain. SMB Support Systems Player Holonis Preps Its Debut at SxSW. GeoMarketing, 6 Mar. 2015. Web. 26 Feb. 2016.
- ^ "The Five Hottest Trends Coming Out of SXSW 2015 - The Social Media Monthly". The Social Media Monthly. Retrieved March 2, 2016.
- ^ Big Assists for Small Retailers, STORES Magazine. 04 May 2015
- ^ Holonis – Your Smarter Marketplace | NewsWatch Review, NewsWatch. 20 April 2015.
- ^ Will the Internet of Things Come of Age in 5 Years?, AdWeek. 13 March 2015.
Patents | Publication Number | Publication Date |
---|---|---|
System and method for internet publishing | WO2013188815 A3 | May 1, 2014 |
Hollis-Eden Pharmaceuticals Patents | Numerous Publications | 1994-2009 |
Needless Injector | USD349958 S | Aug 23, 1994 |